Developing drugs that act on the Alternative Renin Angiotensin System.
 

CONSTANT THERAPEUTICS

DEVELOPING DRUGS THAT ACT ON THE ALTERNATIVE RENIN ANGIOTENSIN SYSTEM

 
 
Dangerous Beauty Home Page.png

We are targeting diseases with significant unmet needs including Duchenne Muscular Dystrophy, Epidermolysis Bullosa, and Ischemic Stroke. 

 
XITRA.png

XITRA

Activation of the Alternative RAS through the Mas and MrgD receptors leads to a variety of biologic effects and the potential to develop drug therapies for a wide range of diseases.

LEARN MORE
Science.png

SCIENCE

The alternative renin angiotensin system (RAS) is a counter regulatory pathway to the classical RAS. The “classical” renin angiotensin system (RAS) comprises Angiotensin Converting Enzyme (ACE), its peptide product Angiotensin II, and the peptide’s receptor, AT1. This system, which controls blood pressure, and fluid and electrolyte balance, was discovered in the first half of the 20th century.

LEARN MORE
Pipeline.png

PIPELINE

Development Pipeline

LEARN MORE
 

 

News and Events

Featured
CONSTANT THERAPEUTICS TXA127 FOR COVID-19 TO ENTER NIH-FUNDED CLINICAL TRIAL AT 60 SITES AROUND THE U.S.

As the focus on the COVID-19 pandemic shifts to raising the number of vaccinated people around the world, U.S. researchers, funded by the NIH, are undertaking a large new clinical trial to find effective treatments, in the belief that while controllable, SARS-Cov-2 and its variants will continue to cause endemic disease in many parts of the world.

Read More →
Constant Therapeutics’ TXA127 to be tested in Multiple Clinical Trials for COVID-19 Patients

Medical Centers in USA, Italy and Israel to Conduct Phase 2 Trials

Read More →

 

 

Contact Us

 

 

Blue Banner.png